Technical Analysis for DNL - Diurnal Group Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical DNL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | 0.70% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.70% | |
| Stochastic Reached Oversold | Weakness | 0.70% | |
| Multiple of Ten Bullish | Other | 0.70% | |
| Wide Bands | Range Expansion | 0.70% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 2 days ago |
| Down 5% | 2 days ago |
| Down 3% | 2 days ago |
| Down 2% | 2 days ago |
| Down 1% | 2 days ago |
Get this analysis on your stocks daily!
Diurnal Group Plc Description
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company's products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism. The Company's products are under various clinical trials, including Chronocort, which is in Phase III clinical trial; Infacort, which is in Phase III clinical trial, and Native Oral Testosterone, which is in Phase I clinical trial.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Clinic Cement Therapy Clinical Trial Alcohols Organ Systems Hormones Idis Thyroid Endocrine System Hypogonadism Testosterone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 97.975 |
| 52 Week Low | 27.0001 |
| Average Volume | 247,983 |
| 200-Day Moving Average | 57.02 |
| 50-Day Moving Average | 66.34 |
| 20-Day Moving Average | 75.85 |
| 10-Day Moving Average | 76.25 |
| Average True Range | 4.45 |
| ADX | 31.93 |
| +DI | 24.45 |
| -DI | 25.11 |
| Chandelier Exit (Long, 3 ATRs ) | 84.63 |
| Chandelier Exit (Short, 3 ATRs ) | 75.95 |
| Upper Bollinger Band | 89.45 |
| Lower Bollinger Band | 62.25 |
| Percent B (%b) | 0.34 |
| BandWidth | 35.86 |
| MACD Line | 2.23 |
| MACD Signal Line | 3.77 |
| MACD Histogram | -1.5473 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 77.80 | ||||
| Resistance 3 (R3) | 77.33 | 74.77 | 76.75 | ||
| Resistance 2 (R2) | 74.77 | 73.16 | 75.00 | 76.40 | |
| Resistance 1 (R1) | 73.13 | 72.17 | 73.95 | 73.60 | 76.05 |
| Pivot Point | 70.57 | 70.57 | 70.98 | 70.80 | 70.57 |
| Support 1 (S1) | 68.93 | 68.96 | 69.75 | 69.40 | 66.95 |
| Support 2 (S2) | 66.37 | 67.97 | 66.60 | 66.60 | |
| Support 3 (S3) | 64.73 | 66.37 | 66.25 | ||
| Support 4 (S4) | 65.20 |
